These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12823504)

  • 1. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies.
    Mayr M; Berek K; Deisenhammer F
    Eur J Neurol; 2003 Jul; 10(4):462-4. PubMed ID: 12823504
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
    Romero López J; Maciñeiras Montero JL
    Med Clin (Barc); 2005 Feb; 124(4):144-5. PubMed ID: 15713245
    [No Abstract]   [Full Text] [Related]  

  • 3. Neutralising antibodies against interferon beta in multiple sclerosis.
    Antonelli G
    Lancet; 2004 Jan; 363(9403):168; author reply 168-9. PubMed ID: 14726180
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple sclerosis: relating MxA transcription to anti-interferon-beta-neutralizing antibodies.
    Hoffmann LA; Krumbholz M; Faber H; Kuempfel T; Starck M; Pöllmann W; Meinl E; Hohlfeld R
    Neurology; 2007 Mar; 68(12):958-9. PubMed ID: 17372138
    [No Abstract]   [Full Text] [Related]  

  • 5. Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-B antibodies in multiple sclerosis.
    Burks JS; Noronha A
    Eur J Neurol; 2007 Jun; 14(6):e8-9; author reply e10-1. PubMed ID: 17539931
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutralising antibodies against interferon beta in multiple sclerosis.
    Mikol D
    Lancet; 2004 Jan; 363(9403):167-8; author reply 168-9. PubMed ID: 14726179
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R; Stürzebecher CS; Kapp JF
    Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
    [No Abstract]   [Full Text] [Related]  

  • 8. Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Whitaker JN
    Arch Neurol; 2001 Aug; 58(8):1301. PubMed ID: 11493175
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis].
    Río J; Tintoré M; Téllez N; Nos C; Galán I; Montalbán X
    Med Clin (Barc); 2005 Feb; 124(4):140-1. PubMed ID: 15713243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term evolution of anti-INFbeta antibodies in IFNbeta-treated MS patients: the London, Canada, MS Clinic experience.
    Kremenchutzky M
    Neurology; 2003 Nov; 61(9 Suppl 5):S29-30. PubMed ID: 14610109
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta.
    Mayorga C; Luque G; Romero F; Guerrero R; Blanca M; Fernandez O
    Int Arch Allergy Immunol; 1999; 118(2-4):368-71. PubMed ID: 10224450
    [No Abstract]   [Full Text] [Related]  

  • 12. Comments on the report of the EFNS task force on IFN-beta antibodies in multiple sclerosis.
    Freedman MS
    Eur J Neurol; 2007 Jun; 14(6):e7; author reply e10-1. PubMed ID: 17539930
    [No Abstract]   [Full Text] [Related]  

  • 13. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract]   [Full Text] [Related]  

  • 14. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H; Stelmasiak Z
    Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of antibodies to interferon beta in patients with multiple sclerosis.
    Pachner AR
    Arch Neurol; 2001 Aug; 58(8):1299-300. PubMed ID: 11493174
    [No Abstract]   [Full Text] [Related]  

  • 16. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients.
    Pachner AR
    Neurology; 2003 Nov; 61(10):1444-6. PubMed ID: 14638976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
    Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
    J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al.
    Menge T; Hartung HP; Kieseier BC
    J Neurol; 2011 May; 258(5):904-7. PubMed ID: 21340521
    [No Abstract]   [Full Text] [Related]  

  • 19. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta.
    Pachner AR; Oger J; Palace J
    Neurology; 2003 Nov; 61(9 Suppl 5):S18-20. PubMed ID: 14610105
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients.
    Pachner AR; Brady J; Steiner I; Narayan K
    J Neurol; 2008 Nov; 255(11):1815-7. PubMed ID: 19031099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.